Flagship leads $80M round for immunotherapy play KSQ

KSQ Therapeutics Inc. (Cambridge, Mass.) plans to use the proceeds from an $80 million series C round to advance its first program -- a modified adoptive T cell immunotherapy -- into the clinic within the next 18 months as a monotherapy for PD-1-resistant solid tumors.

The round was led by existing investor Flagship Pioneering. New investors Baillie Gifford, Cowen, Invus and Lilly Asia Ventures and existing investors Polaris Partners, Arch Venture Partners and Alexandria Equities also participated...